Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Adimi
Parvin
P
Hansen
Flemming
F
Kjaer
Mogens
M
Aabo
Kristian
K
Keldsen
Nina
N
Pfeiffer
Per
P
Sandberg
Erik
E
Jakobsen
Anders
A
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003967:Diarrhea / Q000139:chemically induced; D004338:Drug Combinations; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D009325:Nausea / Q000139:chemically induced; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014498:Uracil / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D004338:Drug Combinations; D003841:Deoxycytidine; D005641:Tegafur; D014498:Uracil; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil